Cost-effectiveness analysis of breast cancer control interventions in Peru

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Zelle, Sten G ^a   Vidaurre, Tatiana ^b   Abugattas, Julio E ^b   Manrique, Javier E ^b   Sarria, Gustavo ^b   Jeronimo, José ^c   Seinfeld, Janice N ^d   Lauer, Jeremy A ^e   Sepulveda, Cecilia R ^e   Venegas, Diego ^f   Baltussen, Rob ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^c PATH   (United States)

^d UNIVERSIDAD DEL PACÍFICO   (Peru)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f MINISTERIO DE SALUD   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER SCREENING; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DISABILITY ADJUSTED LIFE YEAR; EARLY DIAGNOSIS; HEALTH CARE CONCEPTS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAMMOGRAPHY; PERU; URBAN POPULATION; ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; INCIDENCE; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; THEORETICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MIDDLE AGED; MODELS, THEORETICAL; PERU; YOUNG ADULT;

EID: 84892423311     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082575     Document Type: Article

References (65)

1. Lozano-Ascencio R, Gómez-Dantés H, Lewis S, Torres-Sánchez L, López-Carrillo L (2009) Breast cancer trends in Latin America and the Caribbean. Salud Publica Mex 51 Suppl 2: s147-s156. doi:10.1590/S0036-36342009000800004. PubMed: 19967269.
2. Huicho L, Trelles M, Gonzales F, Mendoza W, Miranda J (2009) Mortality profiles in a country facing epidemiological transition: an analysis of registered data. BMC Public Health 9: 47. doi:10.1186/1471-2458-9-47. PubMed: 19187553.
3. Cazap E, Buzaid AC, Garbino C, de la Garza J, Orlandi FJ et al. (2008) Breast cancer in Latin America: results of the Latin American and Caribbean Society of Medical Oncology/Breast Cancer Research Foundation expert survey. Cancer 113: 2359-2365. doi:10.1002/cncr.23834. PubMed: 18837031.
4. Bosetti C, Malvezzi M, Chatenoud L, Negri E, Levi F et al. (2005) Trends in cancer mortality in the Americas, 1970-2000. Ann Oncol 16: 489-511. doi:10.1093/annonc/mdi086. PubMed: 15668262.
5. Instituto Nacional de Enfermedades Neoplásicas (INEN). Perfil Epidemiológico 2008-2009. Available: http://www.inen.sld.pe/portal/ estadisticas/datos-epidemiologicos.html. Accessed 21 November 2012
6. Instituto Regional de Enfermedades Neoplásicas IREN Norte. Registro Hospitalario de Cáncer. Informe al I Semestre 2011. Available: http://www.irennorte.gob.pe/epidemiologia/pdf/informe4.pdf. Accesed 2 December 2012
7. World Health Organization (2008). Global Burden of Disease 2004 update. Available: http://www.who.int/healthinfo/global-burden-disease/estimates- country/en/index.html. Accessed 20 November 2012
8. Coalicion multisectorial "Peru contra el Cancer". Plan nacional para el fortalecimiento de la prevencion y control del cancer el Peru. Lima, Diciembre 2006. Available: http://www.inen.sld.pe/portal/documentos/pdf/Curso/ Plan-Nac-Fort-Prev-Control-cancer.pdf. Accessed 15 October 2012
9. Instituto Nacional de Enfermedades Neoplasticas. Plan Estrategico Institucional 2011-2015. Available: http://www.inen.sld.pe/portal/documentos/ pdf/institucional/Plan-Estrategico/22112011-PEI-2011-2015.pdf. Accessed 15 October 2012
10. Wilson L, Velásquez A, Ponce C (2009) La ley Marco de aseguramiento universal en salud en el Peru: Analisis de beneficios y sistematización del proceso desde su concepción hasta su promulgacion. Rev Peru Med Exp Salud Publica 26(2): 207-217.
11. Plan Esperanza, Ministerio de Salud Peru (2012) Available: ftp://ftp2.minsa.gob.pe/normaslegales/2012/DS009-2012-SA-EP.pdf. Accessed 1 December 2012
12. WHO Chronic Disease Department (CDC) (2012) Breast cancer Burden, Policies and Programmes assessment tool. Inventory by INEN, Peru.
13. ENAHO (2004 - 2011) Actualización metodológica en el tratamiento de la base de datos de la Encuesta Nacional de Hogares-ENAHO.
14. Alcalde-Rabanal JE, Lazo-González O, Nigenda G (2011) The health system of Peru. Salud Publica Mex 53 Suppl 2: s243-s254. PubMed: 21877089.
15. Zelle SG, Baltussen RM (2013) Economic analyses of breast cancer control in low- and middle-income countries: a systematic review. Syst Rev 2: 20. doi:10.1186/2046-4053-2-20. PubMed: 23566447.
16. Ginsberg GM, Lauer JA, Zelle S, Baeten S, Baltussen R (2012) Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ 344: e614. doi:10.1136/bmj.e614. PubMed: 22389347.
17. Groot MT, Baltussen R, Uyl-de Groot CA, Anderson BO, Hortobágyi GN (2006) Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia. Breast J 12 Suppl 1: S81-S90. doi:10.1111/j.1075-122X.2006.00206.x. PubMed: 16430401.
18. Zelle SG, Nyarko KM, Bosu WK, Aikins M, Niëns LM et al. (2012) Costs, effects and cost-effectiveness of breast cancer control in Ghana. Trop Med Int Health 17: 1031-1043. doi:10.1111/j.1365-3156.2012.03021.x. PubMed: 22809238.
19. Hutubessy R, Chisholm D, Edejer TT (2003) Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 1: 8. doi:10.1186/1478-7547-1-8. PubMed: 14687420.
20. WHO CHOICE. Choosing interventions that are cost effective. Available: http://www.who.int/choice/en/. Accessed 22 November 2012
21. Adam T, Lim SS, Mehta S, Bhutta ZA, Fogstad H et al. (2005) Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries. BMJ 331: 1107. doi:10.1136/bmj.331.7525.1107. PubMed: 16282407.
22. Baltussen R, Floyd K, Dye C (2005) Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ 331: 1364. doi:10.1136/bmj.38645.660093.68. PubMed: 16282379.
23. Lancet Global Mental Health G, Chisholm D, Flisher AJ, Lund C, Patel V et al. (2007) Scale up services for mental disorders: a call for action. Lancet 370: 1241-1252. doi:10.1016/S0140-6736(07)61242-2. PubMed: 17804059. Available online at: doi:10.1016/S0140-6736(07)61242-2 Available online at: PubMed: 17804059
24. Ortegón M, Lim S, Chisholm D, Mendis S (2012) Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ 344: e607. doi:10.1136/bmj.e607. PubMed: 22389337.
25. PATH Community based Program for Breast Health, Peru. Available: http://sites.path.org/rh/files/2012/06/PATH-Breast-cancer-proj-Peru-2012.pdf. Accessed 17 October 2012
26. Tsu VD, Jeronimo J, Anderson BO (2013) Why the time is right to tackle breast and cervical cancer in low-resource settings. Bull World Health Organ 91:683-690 | doi: http://dx.doi.org/10.2471/BLT.12.116020.
27. Greene FL, Compton CC, Fritz AG, Greene, Shah J, Winchester P (2006) AJCC Cancer Staging Atlas. New York, NY. Springer, Inc.
28. Lauer JA, Röhrich K, Wirth H, Charette C, Gribble S et al. (2003) PopMod: a longitudinal population model with two interacting disease states. Cost Eff Resour Alloc 1: 6. doi:10.1186/1478-7547-1-6. PubMed: 12773215.
29. Instituto Nacional de Estadistica e Informatica Dirreccion Tecnica de Demografia (INEI). Censo Nacional de Poblacion 2007.
30. Bland KI, Menck HR, Scott-Conner CE, Morrow M, Winchester DJ et al. (1998) The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer 83: 1262-1273. doi:10.1002/(SICI)1097-0142(19980915)83:6. PubMed: 9740094.
31. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A et al. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369: 29-36. doi:10.1016/S0140-6736(07)60028-2. PubMed: 17208639.
32. Whyte S, Cooper KL, Stevenson MD, Madan J, Akehurst R (2011) Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. Value Health 14: 465-474. doi:10.1016/j.jval.2010.10.037. PubMed: 21669371.
33. Purmonen TT, Pänkäläinen E, Turunen JH, Asseburg C, Martikainen JA (2011) Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol 50: 344-352. doi:10.3109/0284186X.2011.553841. PubMed: 21299447.
34. Duffy SW, Gabe R (2005) What should the detection rates of cancers be in breast screening programmes? Br J Cancer 92: 597-600. PubMed: 15668711.
35. National Evaluation Team for Breast cancer screening in the Netherlands (NETB) (2009) National evaluation of breast cancer screening in the Netherlands. Twelfth evaluation Report 1990-2007
36. Bobo JK, Lee NC, Thames SF (2000) Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst 92: 971-976. doi:10.1093/jnci/92.12.971. PubMed: 10861308.
37. Devi BC, Tang TS, Corbex M (2007) Reducing by half the percentage of late-stage presentation for breast and cervix cancer over 4 years: a pilot study of clinical downstaging in Sarawak, Malaysia. Ann Oncol 18: 1172-1176. doi:10.1093/annonc/mdm105. PubMed: 17434897.
38. Kerlikowske K, Smith-Bindman R, Ljung BM, Grady D (2003) Evaluation of abnormal mammography results and palpable breast abnormalities. Ann Intern Med 139: 274-284. doi:10.7326/0003-4819-139-4-200308190-00010. PubMed: 12965983.
39. Ariga R, Bloom K, Reddy VB, Kluskens L, Francescatti D et al. (2002) Fine-needle aspiration of clinically suspicious palpable breast masses with histopathologic correlation. Am J Surg 184: 410-413. doi:10.1016/S0002-9610(02) 01014-0. PubMed: 12433603.
40. Bukhari MH, Arshad M, Jamal S, Niazi S, Bashir S, et al. (2011) Use of fine-needle aspiration in the evaluation of breast lumps. Patholog Res Int 2011: 689521.
41. Nagar S, Iacco A, Riggs T, Kestenberg W, Keidan R (2012) An analysis of fine needle aspiration versus core needle biopsy in clinically palpable breast lesions: a report on the predictive values and a cost comparison. Am J Surg 204: 193-198. doi:10.1016/j.amjsurg.2011.10.018. PubMed: 22464444.
42. Nguansangiam S, Jesdapatarakul S, Tangjitgamol S (2009) Accuracy of fine needle aspiration cytology from breast masses in Thailand. Asian Pac J Cancer Prev 10: 623-626. PubMed: 19827882.
43. Thomas JO, Amanguno AU, Adeyi OA, Adesina AO (1999) Fine needle aspiration (FNA) in the management of palpable masses in Ibadan: impact on the cost of care. Cytopathology 10: 206-210. doi:10.1046/j.1365-2303.1999.00187.x. PubMed: 10390070.
44. Vimpeli SM, Saarenmaa I, Huhtala H, Soimakallio S (2008) Large-core needle biopsy versus fine-needle aspiration biopsy in solid breast lesions: comparison of costs and diagnostic value. Acta Radiol 49: 863-869. doi:10.1080/02841850802235751. PubMed: 18618302.
45. Eberl MM, Phillips RL Jr., Lamberts H, Okkes I, Mahoney MC (2008) Characterizing breast symptoms in family practice. Ann Fam Med 6: 528-533. doi:10.1370/afm.905. PubMed: 19001305.
46. Flobbe K, van der Linden ES, Kessels AG, van Engelshoven JM (2001) Diagnostic value of radiological breast imaging in a non-screening population. Int J Cancer 92: 616-618. doi:10.1002/ijc.1235. PubMed: 11304700.
47. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ et al. (1998) Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 338: 1089-1096. doi:10.1056/NEJM199804163381601. PubMed: 9545356.
48. WHO Commission on Macroeconomics and Health (2011) Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Available: http://whqlibdoc.who.int/publications/ 2001/924154550x.pdf. Accessed 20 June 2011
49. Schwartsmann G (2001) Breast cancer in South America: challenges to improve early detection and medical management of a public health problem. J Clin Oncol 19: 118S-124S. PubMed: 11560986.
50. World Health Organization, Department of Chronic Diseases and Health Promotion. Cancer control: knowledge into action : WHO guide for effective programmes. Available: http://www.who.int/cancer/modules/en/index.html. Accessed 22 November 2012
51. Mittra I, Mishra GA, Singh S, Aranke S, Notani P et al. (2010) A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer 126: 976-984. PubMed: 19697326.
52. Okonkwo QL, Draisma G, der Kinderen A, Brown ML, de Koning HJ (2008) Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst 100: 1290-1300. doi:10.1093/jnci/djn292. PubMed: 18780864.
53. Zotov V, Shyyan R, Program PBCA (2003) Introduction of breast cancer screening in Chernihiv Oblast in the Ukraine: report of a PATH Breast Cancer Assistance Program experience. Breast J 9 Suppl 2: S75-S80. doi:10.1046/j.1524- 4741.9.s2.7.x. PubMed: 12713500.
54. Laxminarayan R, Chow J, Shahid-Salles SA (2006) Intervention Cost-Effectiveness: Overview of Main Messages Disease Control Priorities in Developing Countries (2nd Edition). New York: Oxford University Press. pp. 35-86. DOI: 10.1596/978-0-821-36179-5/Chpt-2.
55. Salomon JA, Carvalho N, Gutiérrez-Delgado C, Orozco R, Mancuso A et al. (2012) Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis. BMJ 344: e355. doi:10.1136/bmj.e355. PubMed: 22389335.
56. Brown ML, Goldie SJ, Draisma G, Harford J, Lipscomb J (2006) Health Service Interventions for Cancer Control in Developing Countries. In: DT JamisonJG BremanAR MeashamG AlleyneM Claeson. Disease Control Priorities in Developing Countries. 2nd ed. Washington (DC).
57. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ et al. (2009) Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 151: 738-747. doi:10.7326/0003-4819-151-10-200911170-00010. PubMed: 19920274.
58. Broekx S, Den Hond E, Torfs R, Remacle A, Mertens R et al. (2011) The costs of breast cancer prior to and following diagnosis. Eur J Health Econ 12: 311-317. doi:10.1007/s10198-010-0237-3. PubMed: 20306109.
59. Radice D, Redaelli A (2003) Breast cancer management: quality-of-life and cost considerations. Pharmacoeconomics 21: 383-396. doi:10.2165/00019053- 200321060-00003. PubMed: 12678566.
60. Anderson BO, Shyyan R, Eniu A, Smith RA, Yip CH et al. (2006) Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J 12 Suppl 1: S3-15. doi:10.1111/j.1075-122X. 2006.00199.x. PubMed: 16430397.
61. Kumar SK (2007) Kerala, India: a regional community-based palliative care model. J Pain Symptom Manage 33: 623-627. doi:10.1016/j.jpainsymman.2007.02. 005. PubMed: 17482058.
62. Walsh D, Rybicki L (2006) Symptom clustering in advanced cancer. Support Care Cancer 14: 831-836. doi:10.1007/s00520-005-0899-z. PubMed: 16482450.
63. Hortobagyi GN (2002) Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol 29: 134-144. doi:10.1016/S0093-7754(02)70137-1. PubMed: 12138408.
64. Vallejos CS, Gómez HL, Cruz WR, Pinto JA, Dyer RR et al. (2010) Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin Breast Cancer 10: 294-300. doi:10.3816/CBC.2010.n.038. PubMed: 20705562.
65. Adjuvant! Online (2012). Adjuvant! Online. Decision making tools for health care professionals. Available: www.adjuvantonline.com. Accessed 1 May 2010